XTX Topco Ltd Buys Shares of 126,957 Immatics N.V. (NASDAQ:IMTX)

XTX Topco Ltd acquired a new stake in shares of Immatics N.V. (NASDAQ:IMTX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 126,957 shares of the company's stock, valued at approximately $573,000. XTX Topco Ltd owned about 0.10% of Immatics at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in IMTX. Suvretta Capital Management LLC purchased a new stake in Immatics in the fourth quarter worth about $36,014,000. T. Rowe Price Investment Management Inc. lifted its stake in shares of Immatics by 43.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,604,777 shares of the company's stock valued at $75,400,000 after buying an additional 3,225,141 shares in the last quarter. Vestal Point Capital LP lifted its stake in shares of Immatics by 67.3% during the 4th quarter. Vestal Point Capital LP now owns 6,275,000 shares of the company's stock valued at $44,615,000 after buying an additional 2,525,000 shares in the last quarter. Braidwell LP lifted its stake in shares of Immatics by 112.7% during the 4th quarter. Braidwell LP now owns 3,503,965 shares of the company's stock valued at $24,913,000 after buying an additional 1,856,400 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP lifted its position in shares of Immatics by 38.7% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 5,414,409 shares of the company's stock valued at $38,496,000 after acquiring an additional 1,509,547 shares in the last quarter. Hedge funds and other institutional investors own 64.41% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently commented on IMTX. Wall Street Zen downgraded Immatics from a "hold" rating to a "strong sell" rating in a research report on Thursday, May 22nd. Deutsche Bank Aktiengesellschaft began coverage on Immatics in a research report on Wednesday, May 28th. They issued a "buy" rating and a $10.00 price objective on the stock. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $14.67.

Immatics Trading Down 2.2%

Shares of NASDAQ:IMTX traded down $0.14 during mid-day trading on Friday, reaching $6.18. The stock had a trading volume of 189,902 shares, compared to its average volume of 354,574. The company has a market cap of $751.18 million, a P/E ratio of -36.35 and a beta of 0.93. Immatics N.V. has a 1 year low of $3.30 and a 1 year high of $13.09. The business's 50 day moving average price is $6.00 and its 200 day moving average price is $5.17.

Immatics (NASDAQ:IMTX - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.04. The firm had revenue of $20.12 million for the quarter, compared to analysts' expectations of $14.92 million. Immatics had a negative return on equity of 4.52% and a negative net margin of 14.73%. Analysts predict that Immatics N.V. will post -0.72 earnings per share for the current fiscal year.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.